3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Neoplasms by Site, Skin and Connective Tissue Diseases, autosomal dominant Parkinson disease 4, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 32026-10-06NCT06312176
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorderRecruitingPhase 32026-09-15NCT06492616
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 32026-08-26NCT07128199